Fig. 2.From: A retrospective study of treatment persistence and adherence to α-blocker plus antimuscarinic combination therapies, in men with LUTS/BPH in the NetherlandsMedian time to discontinuation for FDC versus concomitant therapy α-blocker plus antimuscarinic. CI: confidence intervals; FDC: fixed-dose combination; HR: hazard ratio; TTD: time to discontinuationBack to article page